The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children

Riccardo Masetti, Vanessa Guidi, Laura Ronchini, Nicola Salvatore Bertuccio, Franco Locatelli, Andrea Pession

Research output: Contribution to journalReview article

Abstract

Pediatric non-Down-syndrome acute megakaryoblastic leukemia (non-DS-AMKL) is a heterogeneous subtype of leukemia that has historically been associated with poor prognosis. Until the advent of large-scale genomic sequencing, the management of patients with non-DS-AMKL was very difficult due to the absence of reliable biological prognostic markers. The sequencing of large cohort of pediatric non-DS-AMKL samples led to the discovery of novel genetic aberrations, including high-frequency fusions, such as CBFA2T3-GLIS2 and NUP98-KDM5 A, as well as less frequent aberrations, such as HOX rearrangements. These new insights into the genetic landscape of pediatric non-DS-AMKL has allowed refining the risk-group stratification, leading to important changes in the prognostic scenario of these patients. This review summarizes the most important molecular pathogenic mechanisms of pediatric non-DS-AMKL. A critical discussion on how novel genetic abnormalities have refined the risk profile assessment and changed the management of these patients in clinical practice is also provided.

Original languageEnglish
Pages (from-to)132-138
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Volume138
DOIs
Publication statusE-pub ahead of print - Apr 15 2019

    Fingerprint

Cite this